IRIS
TASSONE, PIERFRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.412
AS - Asia 2.619
EU - Europa 2.582
SA - Sud America 195
AF - Africa 40
Continente sconosciuto - Info sul continente non disponibili 24
OC - Oceania 17
Totale 10.889
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.157
SG - Singapore 1.740
IT - Italia 1.213
CN - Cina 454
SE - Svezia 395
GB - Regno Unito 320
DE - Germania 266
CA - Canada 217
BR - Brasile 161
IN - India 134
FI - Finlandia 95
NL - Olanda 52
HK - Hong Kong 47
FR - Francia 37
RO - Romania 36
MX - Messico 27
PK - Pakistan 27
ES - Italia 26
RU - Federazione Russa 26
BD - Bangladesh 24
JO - Giordania 23
EU - Europa 22
UA - Ucraina 22
IR - Iran 19
JP - Giappone 19
CZ - Repubblica Ceca 17
ID - Indonesia 17
IQ - Iraq 17
PL - Polonia 17
TR - Turchia 17
ZA - Sudafrica 16
SA - Arabia Saudita 14
VN - Vietnam 14
AT - Austria 13
AU - Australia 12
LT - Lituania 11
CL - Cile 9
KR - Corea 9
PT - Portogallo 9
AE - Emirati Arabi Uniti 8
EC - Ecuador 7
EG - Egitto 7
IE - Irlanda 7
CO - Colombia 6
EE - Estonia 6
MA - Marocco 6
MY - Malesia 5
CY - Cipro 4
IL - Israele 4
LB - Libano 4
NZ - Nuova Zelanda 4
PH - Filippine 4
TW - Taiwan 4
VE - Venezuela 4
BG - Bulgaria 3
CH - Svizzera 3
ET - Etiopia 3
GT - Guatemala 3
HN - Honduras 3
LK - Sri Lanka 3
NG - Nigeria 3
PE - Perù 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AR - Argentina 2
GR - Grecia 2
HR - Croazia 2
HU - Ungheria 2
NP - Nepal 2
PS - Palestinian Territory 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AZ - Azerbaigian 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
DZ - Algeria 1
GE - Georgia 1
JM - Giamaica 1
KE - Kenya 1
KI - Kiribati 1
NI - Nicaragua 1
OM - Oman 1
PY - Paraguay 1
SN - Senegal 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 10.889
Salva come PNG Salva come JPEG
Città #
Chandler 906
Singapore 735
Santa Clara 442
Milan 387
Lawrence 383
Princeton 383
Chicago 267
London 246
Wilmington 224
Munich 209
Ashburn 175
Ottawa 165
Catanzaro 153
Des Moines 111
Boardman 84
Beijing 72
Turku 70
Los Angeles 49
Shanghai 48
Rome 43
Guangzhou 41
Pune 39
New York 37
Hong Kong 35
Norwalk 32
The Dalles 31
Redwood City 30
Redmond 28
San Francisco 27
Helsinki 25
Naples 25
Brooklyn 22
Parma 19
Columbus 18
São Paulo 17
San Nicola Manfredi 16
Amman 15
Warsaw 15
Chennai 14
Olomouc 14
West Jordan 14
Dallas 13
Horia 13
Mountain View 13
Phoenix 13
Reggio Calabria 13
Atlanta 12
Boston 12
Carbonia 12
Delhi 12
Montreal 12
Palermo 12
Timisoara 12
Vallefiorita 12
Washington 12
Augusta 11
Cosenza 11
Hanover 11
Amsterdam 10
Charlotte 10
Madrid 10
Mexico City 10
Stockholm 10
Zhengzhou 10
Aversa 9
Denver 9
Jiaxing 9
Manchester 9
Seattle 9
Shenzhen 9
Afragola 8
Ahmedabad 8
Bari 8
Cicciano 8
Council Bluffs 8
Ercolano 8
Irbid 8
Las Vegas 8
Santo Stefano di Rogliano 8
Tokyo 8
Toronto 8
Xi'an 8
Ankara 7
Dhaka 7
Kaunas 7
Rio de Janeiro 7
Settingiano 7
Spezzano della Sila 7
Catania 6
Frankfurt am Main 6
Hanoi 6
Jeddah 6
Johannesburg 6
Lucknow 6
Melito di Porto Salvo 6
Nanjing 6
Richmond 6
Riyadh 6
Sezze 6
Vancouver 6
Totale 6.196
Salva come PNG Salva come JPEG
Nome #
Pharmacogenetics/Pharmacogenomics of Drug-Metabolizing Enzymes and Transporters 357
A Novel Bispecific T-Cell Engager (CD1a x CD3ε) BTCE Is Effective against Cortical-Derived T Cell Acute Lymphoblastic Leukemia (T-ALL) Cells 85
miR-22 suppresses DNA ligase III addiction in multiple myeloma 84
Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study 78
miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review 69
A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine. 65
MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells 62
Identification of polymorphic variants associated with erlotinib-related skin toxicity in advanced non-small cell lung cancer patients by DMET microarray analysis 60
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro 59
Evidence of a founder mutation of BRCA1 in a highly homogeneous population from southern Italy with breast/ovarian cancer 58
Non-coding RNAs in cancer: Platforms and strategies for investigating the genomic "dark matter" 58
LNA-Gapmer Antisense Oligonucleotides Targeting the Oncogenic Lncrna MALAT1 Trigger Anti-Multiple Myeloma Activity By Proteasome Blockade 56
Differential microRNAs expression profile in coronary thrombi from patients with no-reflow after primary PCI 55
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types 55
A 5 ' regulatory sequence containing two Ets motifs controls the expression of the Wiskott-Aldrich syndrome protein (WASP) gene in human hematopoietic cells 54
Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia 54
Raman Spectroscopic Stratification of Multiple Myeloma Patients Based on Exosome Profiling 53
A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer 52
DMET-Analyzer: automatic analysis of Affymetrix DMET Data 52
Evidence of shared epitopic reactivity among independent B-cell clones in Chronic Lymphocytic Leukemia patients 52
A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells 51
Molecular and clinical types of plasma cell dyscrasias are associated with distinct expression patterns of long noncoding RNAs 51
An interleukin-6 antagonist modified for bone targeting preserves anti-myeloma biological activity 50
MYC-MIR-22 REGULATORY LOOP MODULATES LENALIDOMIDE ACTIVITY IN MULTIPLE MYELOMA CELLS 49
Identifying prognostic markers for multiple myeloma through integration and analysis of MMRF-CoMMpass data 49
MIR-21 SUPPRESSION IMPAIRS TH17 RELATED BONE DISEASE IN MULTIPLE MYELOMA 48
Discovery, Functional Characterization and Therapeutic Targeting of Lnc-17-92 Metabolic Signaling in Multiple Myeloma 48
Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease 47
The First-In-Class Anti-AXL×CD3ε Pronectin™-Based Bispecific T-Cell Engager Is Active in Preclinical Models of Human Soft Tissue and Bone Sarcomas 46
Whole gene expression profiling shows a differential transcriptional response to CISPLATINUM in BRCA-1 defective versus BRCA1-reconstituted breast cancer cells 46
Aberrant Glycosylation as Biomarker for Cancer: Focus on CD43 46
A peroxisome proliferator-activated receptor gamma (PPARG) polymorphism is associated with zoledronic acid-related osteonecrosis of the jaw in multiple myeloma patients: analysis by DMET microarray profiling 46
miR-21 antagonism abrogates Th17 tumor promoting functions in multiple myeloma 46
A novel monoclonal antibody recognizing human thymocytes and B-cell chronic lymphocytic leukemia cells 45
Differential sensitivity of BRCA1-mutated HCC1937 human breast cancer cells to microtubule-interfering agents 44
Error-prone DNA repair pathways as determinants of immunotherapy activity: an emerging scenario for cancer treatment 44
Distinctive germline expression of class i human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade 44
Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma. 44
A systematic review and meta-analysis of randomized trials on the role of targeted therapy in the management of advanced gastric cancer: Evidence does not translate? 43
Differential expression of UN1, early thymocyte-associated sialoglycoprotein, in breast normal tissue, benign disease and carcinomas 43
ACTIVATION OF GPER SIGNALING AS A POTENTIAL THERAPEUTIC STRATEGY AGAINST WALDENSTROM MACROGLOBULINEMIA 43
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma 42
A Prognostic and Carboplatin Response Predictive Model in Ovarian Cancer: A Mono-Institutional Retrospective Study Based on Clinics and Pharmacogenomics 41
Mir-34: a new weapon against cancer? 41
A gene expression inflammatory signature specifically predicts multiple myeloma evolution and patients survival 41
Impact of natural dietary agents on multiple myeloma prevention and treatment: molecular insights and potential for clinical translation. 41
Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation 40
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells 40
Pembrolizumab-Induced Psoriasis in Metastatic Melanoma: Activity and Safety of Apremilast, a Case Report 40
Anti-MALAT1 synthetic oligonucleotides target the proteasome and exert anti-multiple myeloma activity 40
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma 40
DmetTM genotyping: Tools for biomarkers discovery in the era of precision medicine 40
DMET-miner: Efficient learning of association rules from genotyping data for personalized medicine 40
Mir-221/222 are promising targets for innovative anticancer therapy 39
Modulation of Exosomal microRNA in patients with severe Aortic Stenosis after Transcatheter Aortic Valve Implantation (TAVI) 39
Biochemical modification of an Interleukin-6 antagonist to target myeloma cells in the bone marrow microenvironment 39
HLA class I, NKG2D and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells 39
Allometric scaling approaches for predicting human pharmacokinetic of a locked nucleic acid oligonucleotide targeting cancer-associated miR-221 39
Mir-22 modulates lenalidomide activity by counteracting myc addiction in multiple myeloma 39
Synthesis and preliminary evaluation of the anti-cancer activity on A549 lung cancer cells of a series of unsaturated disulfides. 38
[Extended subcutaneous mastectomy. A new type of operation in non-destructive surgery of breast neoplasms]. FT La mastectomia sottocutanea allargata. Un nuovo tipo d'intervento nella chirurgia non demolitiva della neoplasia mammaria. 38
Association between gene and miRNA expression profiles and stereotyped subset #4 B-cell receptor in chronic lymphocytic leukemia 38
Associazione di antagonisti di IL-6 e farmaci anti-proliferativi (depositato il 10.3.2005 n. RM2005A000103) 38
GOLFIG Chemo-Immunotherapy in Metastatic Colorectal Cancer Patients. A Critical Review on a Long-Lasting Follow-Up 38
Early blood rise in auto-antibodies to nuclear and smooth muscle antigens is predictive of prolonged survival and autoimmunity in metastatic-non-small cell lung cancer patients treated with PD-1 immune-check point blockade by nivolumab 38
Autoimmune colitis and neutropenia in adjuvant anti-PD-1 therapy for malignant melanoma: efficacy of Vedolizumab, a case report 38
Exploiting DNA Ligase III addiction of multiple myeloma by flavonoid Rhamnetin 37
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity. 37
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 37
A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma 37
Transcriptional regulation of the mismatch repair gene hMLH1 37
A35 SINGLE NUCLEOTIDE POLYMORPHISMS OF THE ABCG1 AND ABCC5 TRANSPORTER GENES CORRELATE TO IRINOTECAN-ASSOCIATED GASTROINTESTINAL TOXICITY IN COLORECTAL CANCER PATIENTS AS ASSESSED BY DMET MICROARRAY PROFILING 37
Evidence of shared epitopic reactivity among independent B-cell clones in chronic lymphocytic leukemia patients 37
Mmrf-commpass data integration and analysis for identifying prognostic markers 37
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma. 36
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: The GOLFIG-2 multicentric open-label randomized phase III trial 36
Polymorphic variants in NR1I3 and UGT2B7 predict taxane neurotoxicity and have prognostic relevance in breast cancer patients: a case-control study. 36
A retrospective analysis of pegylated liposomal doxorubicin in ovarian cancer: do we still need it? 36
[Magnesium salts in the treatment of ventricular tachycardia]. FT I sali di magnesio nel trattamento della tachicardia ventricolare. 36
Anti-tumor Activity and Epigenetic Impact of the Polyphenol Oleacein in Multiple Myeloma 36
Aurora Kinase A expression predicts platinum-resistance and adverse outcome in high-grade serous ovarian carcinoma patients 36
Influence of the fabrication accuracy of hot-embossed PCL scaffolds on cell growths 36
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92 36
A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells 36
Chromene Derivatives as Selective TERRA G-Quadruplex RNA Binders with Antiproliferative Properties 35
Purification and characterization of a human sialoglycoprotein antigen expressed in immature thymocytes and fetal tissues 35
Epigenetic modifications in multiple myeloma: recent advances on the role of DNA and histone methylation 35
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell-mediated-cytotoxicity (ADCC) 35
Second-line treatment of non-small cell lung cancer by biweekly gemcitabine and docetaxel plus /- granulocyte-macrophage colony stimulating factor and low dose aldesleukine 35
Identification by differential display of cDNA sequences regulated during hematopoietic differentiation and in leukemias 35
Activation of the Non-Canonical Estrogen Receptor Gper As a Novel Therapeutic Strategy Against Waldenstrom Macroglobulinemia 35
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis 35
Distinctive role of the systemic inflammatory profile in non-small-cell lung cancer younger and elderly patients treated with a pd-1 immune checkpoint blockade: A real-world retrospective multi-institutional analysis 35
TERRA G-quadruplex stabilization as a new therapeutic strategy for multiple myeloma 34
A MIR17HG-derived Long Noncoding RNA Provides an Essential Chromatin Scaffold for Protein Interaction and Myeloma Growth 34
Targeting PI3K and RAD51 in Barrett's Adenocarcinoma: Impact on DNA Damage Checkpoints, Expression Profile and Tumor Growth 34
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias 34
BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cellsBritish Journal of cancer 34
Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma 34
In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma 34
Totale 4.686
Salva come PNG Salva come JPEG
Categoria #
all - tutte 158.456
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 158.456
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021516 51 20 12 23 63 53 33 26 73 82 65 15
2021/20221.151 27 6 17 333 87 20 29 249 114 97 149 23
2022/20232.838 787 108 110 204 299 234 23 198 425 171 228 51
2023/20241.557 347 158 127 110 104 379 45 61 13 51 65 97
2024/20254.484 615 274 203 134 251 564 126 163 510 266 448 930
2025/2026318 318 0 0 0 0 0 0 0 0 0 0 0
Totale 11.214